UNSPSC 50501519: Doxercalciferol

This classification denotes a vitamin d analog with the molecular formula C28H44O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 3DIZ9LF5Y9, chemically known as vitamin d2, 1alpha-hydroxy- but more generally known as doxercalciferol, which bears U.S. National Institutes of Health Compound Identifier 5281107. European Medicines Agency schedules Doxercalciferol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01826MIG.

The term DOXERCALCIFEROL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 14, No. 3, 2000, List 44). World Health Organization schedules doxercalciferol in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.

UNSPSC 50501519 Doxercalciferol, a Commodity code, covers procurement of this active vitamin D analog pharmaceutical. State and local governments purchase doxercalciferol primarily through Medicaid programs, public health departments, and correctional facilities to treat secondary hyperparathyroidism in patients with chronic kidney disease. The drug is also acquired by state and county health systems, Veterans Affairs facilities where state contracting applies, and institutional care settings. Doxercalciferol is typically procured as an injectable or oral formulation through pharmaceutical supply contracts, group purchasing agreements, and state Medicaid formulary agreements. Issuing bodies soliciting under this code include state Medicaid agencies, state departments of health, county health departments, state prison systems, and public hospital networks.

The source provides no recent state or local contract opportunities tagged to UNSPSC 50501519. Without posted RFP, RFQ, IFB, or ITB notices in the data block, the geographic distribution and current market activity for doxercalciferol procurement cannot be characterized from recent solicitations.